Jefferies Upgrades AstraZeneca to Buy, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Peter Welford has upgraded AstraZeneca (NASDAQ:AZN) from Hold to Buy and raised the price target from $66.5 to $80.
September 25, 2023 | 8:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's stock has been upgraded to Buy from Hold by Jefferies, with a raised price target of $80, up from $66.5.
The upgrade from Hold to Buy indicates a positive outlook for AstraZeneca's stock. The raised price target suggests that the analyst believes the stock has potential for significant growth, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100